Experimental and clinical studies indicate that ITs may have a role as adjuvant therapy in selected categories of patients with persistent minimal or low burden disease, following conventional or high-dose chemotherapy. Main efforts in the future should be focused on defining optimal administration regimens and on reducing immunogenicity and toxic side effects.

Pasqualucci, L., Flenghi, L., Terenzi, A., Bolognesi, A., Stirpe, F., Bigerna, B., et al. (1995). Immunotoxin therapy of hematological malignancies. HAEMATOLOGICA, 80(6), 546-556.

Immunotoxin therapy of hematological malignancies

Bolognesi A.;Stirpe F.;
1995

Abstract

Experimental and clinical studies indicate that ITs may have a role as adjuvant therapy in selected categories of patients with persistent minimal or low burden disease, following conventional or high-dose chemotherapy. Main efforts in the future should be focused on defining optimal administration regimens and on reducing immunogenicity and toxic side effects.
1995
Pasqualucci, L., Flenghi, L., Terenzi, A., Bolognesi, A., Stirpe, F., Bigerna, B., et al. (1995). Immunotoxin therapy of hematological malignancies. HAEMATOLOGICA, 80(6), 546-556.
Pasqualucci, L.; Flenghi, L.; Terenzi, A.; Bolognesi, A.; Stirpe, F.; Bigerna, B.; Falini, B.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1008501
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 25
social impact